Vise Technologies Inc. Grows Holdings in Danaher Co. (NYSE:DHR)

Vise Technologies Inc. boosted its stake in Danaher Co. (NYSE:DHR - Free Report) by 110.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,671 shares of the conglomerate's stock after acquiring an additional 3,508 shares during the quarter. Vise Technologies Inc.'s holdings in Danaher were worth $1,531,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Connecticut Wealth Management LLC boosted its stake in Danaher by 1.1% during the 4th quarter. Connecticut Wealth Management LLC now owns 11,669 shares of the conglomerate's stock worth $2,679,000 after purchasing an additional 128 shares during the last quarter. Gordian Capital Singapore Pte Ltd raised its holdings in shares of Danaher by 400.0% during the 4th quarter. Gordian Capital Singapore Pte Ltd now owns 7,000 shares of the conglomerate's stock worth $1,607,000 after acquiring an additional 5,600 shares during the period. Mosaic Family Wealth Partners LLC raised its holdings in shares of Danaher by 23.0% during the 4th quarter. Mosaic Family Wealth Partners LLC now owns 1,613 shares of the conglomerate's stock worth $370,000 after acquiring an additional 302 shares during the period. Harmony Asset Management LLC raised its holdings in shares of Danaher by 12.7% during the 4th quarter. Harmony Asset Management LLC now owns 1,594 shares of the conglomerate's stock worth $366,000 after acquiring an additional 179 shares during the period. Finally, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp raised its holdings in shares of Danaher by 11.9% during the 4th quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 124,466 shares of the conglomerate's stock worth $28,571,000 after acquiring an additional 13,237 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DHR. Raymond James reiterated a "market perform" rating on shares of Danaher in a report on Monday, February 3rd. Wall Street Zen lowered Danaher from a "buy" rating to a "hold" rating in a research note on Saturday. Robert W. Baird reduced their price objective on shares of Danaher from $231.00 to $225.00 and set an "outperform" rating on the stock in a report on Wednesday, April 23rd. Royal Bank of Canada restated an "outperform" rating and issued a $250.00 price objective on shares of Danaher in a report on Wednesday, April 23rd. Finally, Stifel Nicolaus upgraded shares of Danaher from a "hold" rating to a "buy" rating and set a $260.00 price objective on the stock in a report on Friday, March 14th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, Danaher presently has a consensus rating of "Moderate Buy" and an average target price of $263.24.

Insider Buying and Selling at Danaher

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the transaction, the executive vice president now directly owns 15,179 shares of the company's stock, valued at $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction on Monday, May 12th. The shares were sold at an average price of $196.74, for a total transaction of $245,925,000.00. Following the completion of the transaction, the chairman now directly owns 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by insiders.

Danaher Stock Up 2.4%

Shares of NYSE:DHR traded up $4.48 during trading hours on Tuesday, reaching $189.02. The stock had a trading volume of 2,990,603 shares, compared to its average volume of 3,473,399. Danaher Co. has a 1 year low of $171.00 and a 1 year high of $281.70. The firm's 50 day moving average is $194.50 and its 200-day moving average is $214.85. The stock has a market capitalization of $135.28 billion, a price-to-earnings ratio of 35.80, a P/E/G ratio of 2.66 and a beta of 0.80. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a net margin of 16.33% and a return on equity of 10.82%. Research analysts predict that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 annualized dividend and a yield of 0.68%. Danaher's dividend payout ratio is currently 24.85%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.